Sartorius Stedim Biotech S.A. (SRTOY) Stock Price & Analysis
Sartorius Stedim Biotech S.A. (SRTOY) — price $23.50 (-0.97%), as of the Oct 2, 2026 trading session; market cap $229B.
Educational signal · not a buy or sell recommendation · How to read this
Sartorius Stedim Biotech S.A. · SRTOY · Healthcare · Medical - Instruments & Supplies
Sartorius Stedim Biotech S.A. operates globally, providing essential instruments and consumables to the biopharmaceutical industry. Their product range is extensive, featuring items such as cell lines, cell culture growth media, and bioreactors.
Price as of Oct 2, 2026
Key Statistics
No publishable V2 score is available for this stock yet.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $23.50 | |
| Change on the day | -0.97% | |
| 52-week range | $17.25 – $26.54 | |
| Market capitalisation | $229B | |
| Price / earnings (trailing) | 68.94 | |
| Shares traded on the day | 3.2K | |
| Beta (volatility vs the S&P 500) | 1.14 | |
| Dividends per share (last 12 months) | $0.08 | |
| Dividend yield (last 12 months) | 0.35% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results
- · Earnings results
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Other perspectives
Council score for Sartorius Stedim Biotech (SRTOY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 24, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: May 2, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On May 2, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the SRTOY film — every key number, told as a short cinematic story
~2 min · open the film
What is Sartorius Stedim Biotech (SRTOY), and what does it report?
Short answer · as of
Sartorius Stedim Biotech S.A. operates globally, providing essential instruments and consumables to the biopharmaceutical industry. Their product range is extensive, featuring items such as cell lines, cell culture growth media, and bioreactors. Healthcare / Medical Instruments & Supplies Headquarters: Zone Industrielle Les Paluds, Aubagne, PAC, 13781, FR. It employs 10,265 people and is led by Rene Faber. In Q2 FY2026 it reported revenue of $871M and net income of $106M. The market values it at $229B.
What do the latest results show for Sartorius Stedim Biotech (SRTOY)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $871M.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $898.51M Jan 26, 2026
- Latest report · revenue estimate
- $770.28M Jan 26, 2026
- Latest report · revenue vs estimate
- Above estimate Jan 26, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Jan 26, 2026 | $898.51M | $770.28M | $0.0057 | Not available |
| Oct 16, 2025 | $965.86M | Not available | $0.0090 | Not available |
| Jul 22, 2025 | $877.19M | $779.47M | $0.0812 | Not available |
| Apr 16, 2025 | $816.27M | $718.49M | $0.0965 | Not available |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $871M | $106M | $0.01 (diluted) |
| Q1 FY2026 | $866M | $100M | $0.01 (diluted) |
| Q4 FY2025 | $856M | $41M | $0.01 (diluted) |
| Q3 FY2025 | $787M | $72M | $0.01 (diluted) |
What are the financial strengths and risks for Sartorius Stedim Biotech (SRTOY)?
Short answer
The distress and quality screens read Altman Z 34.57 · Piotroski F 7. Trailing ratios: ROE 7.1% · ROA 3.7% · current ratio 1.16 · earnings yield 1.4% · free-cash-flow yield 1.1%.
How is Sartorius Stedim Biotech scored?
Research dated 2026-09-12.
Compared with a conventional laboratory-instrument vendor, Sartorius Stedim participates in much more of the customer’s production chain. Its portfolio connects cell lines and media with bioreactors, separation, purification, fluid management, secure storage and workflow analytics.
That breadth ties demand to biopharmaceutical development and manufacturing activity rather than isolated equipment replacement. The useful comparison is therefore the balance among equipment, consumables, services and software, not healthcare-instrument valuation multiples alone.
| Company | Price | Market value | Score |
|---|---|---|---|
| $189.90 Sep 25, 2026 | $294B | — Model unavailable | |
| $168.91 Oct 2, 2026 | $77.6B | — Model unavailable | |
| $12.43 Oct 2, 2026 | $112B | — Model unavailable | |
| $37.01 Oct 2, 2026 | $164B | — Model unavailable | |
| $391.95 Oct 2, 2026 | $138B | — 5-pillar · not comparable | |
| $176.80 Oct 2, 2026 | $48.7B | — 5-pillar · not comparable | |
| $218.89 Oct 2, 2026 | $31.8B | — 5-pillar · not comparable | |
| $63.76 Oct 2, 2026 | $31.1B | — 5-pillar · not comparable | |
| $35.61 Oct 2, 2026 | $30.1B | — 5-pillar · not comparable | |
| $364.98 Oct 2, 2026 | $25.7B | — 5-pillar · not comparable | |
| $23.49 Oct 2, 2026 | $12.1B | — 5-pillar · not comparable | |
| $56.91 Oct 2, 2026 | $11.1B | — 5-pillar · not comparable |
The comparison model is unavailable. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
Sartorius Stedim Biotech Healthcare Stock: Key Questions Answered
Research dated 2026-09-12; the answers below are from that research, and the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What makes Sartorius Stedim more than a medical-instruments supplier?
Its products span the bioprocess itself, from cell cultivation and fermentation through filtration, purification, storage and transport. Services and analytics software extend that role beyond selling laboratory hardware.
Why do cell and gene therapy kits matter to Sartorius Stedim?
Presterilized kits and hollow-fiber membrane devices place Sartorius Stedim inside specialized cell and gene therapy processes. They broaden the portfolio from core bioreactors into fluid handling, separation and material transfer.
What is the SRTOY stock price today?
The last price recorded on this page for Sartorius Stedim Biotech S.A. (SRTOY) is $23.50, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
Does SRTOY pay a dividend?
Yes. Sartorius Stedim Biotech S.A. (SRTOY) shows a trailing 12-month dividend yield of 0.35%, as of Oct 2, 2026, in the data on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (32 figures)
The 32 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 26 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $23.50 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T21:14:20.930Z. | |
px.change | Change on the day | -0.97% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalization | $229B | FMP | Financial Modeling Prep (FMP) quote — Provider market cap uses the share class it prices; a company with more than one class may show a larger total elsewhere. Market cap record date: 2026-10-02. Source capture time was not supplied. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
id.business_summary | Business description (FMP excerpt) | Sartorius Stedim Biotech S.A. operates globally, providing essential instruments and consumables to the biopharmaceutical industry. Their product range is extensive, featuring items such as cell lines, cell culture growth media, and bioreactors. | FMP | Financial Modeling Prep (FMP) company profile — Deterministic excerpt derived from id.description; source and date describe the input fact, not a new provider observation | |
px.change_abs | Change on the day, in dollars | −$0.2307 | FMP | Financial Modeling Prep (FMP) · quote | |
px.pe | Price / earnings (trailing) | 68.94 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 3.2K | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 1.14 | FMP | Financial Modeling Prep (FMP) company profile | |
id.sector | Sector / industry (provider taxonomy) | Healthcare / Medical Instruments & Supplies | FMP | Financial Modeling Prep (FMP) company profile | |
id.hq | Headquarters | Zone Industrielle Les Paluds, Aubagne, PAC, 13781, FR | FMP | Financial Modeling Prep (FMP) company profile | |
id.employees | Employees | 10,265 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Rene Faber | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
fin.q_revenue | Revenue, Q2 FY2026 | $871M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q2 FY2026 | $106M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
earn.history.depth.2026-01-26.revenue_actual | Revenue · reported — report date 2026-01-26 | $898.51M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-26.revenue_estimated | Revenue · estimate — report date 2026-01-26 | $770.28M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-26.eps_actual | EPS · reported — report date 2026-01-26 | $0.0057 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-16.revenue_actual | Revenue · reported — report date 2025-10-16 | $965.86M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-16.eps_actual | EPS · reported — report date 2025-10-16 | $0.0090 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-07-22.revenue_actual | Revenue · reported — report date 2025-07-22 | $877.19M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-07-22.revenue_estimated | Revenue · estimate — report date 2025-07-22 | $779.47M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-07-22.eps_actual | EPS · reported — report date 2025-07-22 | $0.0812 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-04-16.revenue_actual | Revenue · reported — report date 2025-04-16 | $816.27M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-04-16.revenue_estimated | Revenue · estimate — report date 2025-04-16 | $718.49M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-04-16.eps_actual | EPS · reported — report date 2025-04-16 | $0.0965 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed |
UNRECORDED — 3 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $17.25 – $26.54 | UNRECORDED | Stored company-profile observation — Captured 2026-10-03 | |
fin.scores | Distress and quality screens | Altman Z 34.57 · Piotroski F 7 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 7.1% · ROA 3.7% · current ratio 1.16 · earnings yield 1.4% · free-cash-flow yield 1.1% | — | UNRECORDED | Stored key metrics — Date unknown |
COMPUTED — 3 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $0.08 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 1 split-adjusted declared dividend with an ex-date in the 365 days to 2026-10-04, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 0.35% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | |
earn.history.depth.2026-01-26.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($898.51M) with the recorded estimate ($770.28M) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
Fact-family notes
- Earnings-history note. Source series as of 2026-01-26. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-01-26.revenue_actual,earn.history.depth.2026-01-26.revenue_estimated,earn.history.depth.2026-01-26.revenue_actual.comparison,earn.history.depth.2026-01-26.eps_actual,earn.history.depth.2025-10-16.revenue_actual,earn.history.depth.2025-10-16.eps_actual,earn.history.depth.2025-07-22.revenue_actual,earn.history.depth.2025-07-22.revenue_estimated,earn.history.depth.2025-07-22.eps_actual,earn.history.depth.2025-04-16.revenue_actual,earn.history.depth.2025-04-16.revenue_estimated,earn.history.depth.2025-04-16.eps_actual.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-12
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Sector / industry (provider taxonomy) | Healthcare / Medical - Instruments & Supplies | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Business description | Sartorius Stedim Biotech S.A. operates globally, providing essential instruments and consumables to the biopharmaceutical industry. Their product range is extensive, featuring items such as cell lines, cell culture growth media, and bioreactors. The company also supplies solutions for critical processes like the separation, purification, and concentration of biological materials, alongside systems for the secure storage and transport of both intermediate and final biological products. Furthermore, they offer specialized single-use and reusable hollow-fiber membrane devices, as well as presterilized kits, which are vital for cell and gene therapy applications. Beyond products, Sartorius Stedim Biotech delivers a suite of services covering cell cultivation, fermentation, filtration, purification, and fluid management, in addition to cell harvesting and other sophisticated solutions designed to optimize bioprocesses. They also develop data analytics software to model and improve the workflows involved in biopharmaceutical development and manufacturing. The company caters to a diverse clientele, including pharmaceutical, food, and chemical manufacturers, as well as various research and development institutions. Founded in 1870, Sartorius Stedim Biotech S.A. is headquartered in Aubagne, France, and functions as a subsidiary of Sartorius AG. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Trailing twelve-month ratio set | Quick ratio: 0.55; Current ratio: 1.16; Debt to equity: 0.57; Net margin: 9.7%; Gross margin: 44.9%; Operating margin: 19.4%; Return on assets: 3.7%; Return on equity: 7.1% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
Data provided for informational purposes only.